



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete If Known	
Application Number	Unassigned
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSA et al.
Group Art Unit	Unassigned 1625
Examiner Name	Unassigned ZNDAVIS
Attorney Docket Number	38005-0178

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₈
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
Y	A05	EP	0 221 847	A2	Ciba-Geigy AG	5/13/1987		
Y	A06	WO	97/26265	A1	Novo Nordisk A/S	7/24/1997		
Y	A07	WO	97/41097	A2	Dr. Reddy's Research Foundation	11/6/1997		
Y	A08	WO	98/08871	A1	Novo Nordisk A/S	3/5/1998		
Y	A09	WO	99/03861	A1	Novo Nordisk A/S	1/28/1999		
Y	A10	WO	99/15525	A1	Sanofi	4/1/1999		
Y	A11	WO	00/40569	A1	Alizyme Therapeutics Limited	7/13/2000		
Y	A12	WO	00/63208	A1	Novo Nordisk A/S	10/26/2000		
Y	A13	WO	00/64888	A1	Aventis Pharmaceuticals	11/2/2000		

Examiner Signature	Zane N Davis	Date Considered	1/12/2005
--------------------	--------------	-----------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete If Known	
Application Number	Unassigned
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEF
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0178

RECEIVED
15/2003
1600/2900

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
And	A14	WO	00/64876	A1	Aventis Pharmaceuticals	11/2/2000	
↑	A15	WO	00/66585	A1	Neurogen Corp.	11/9/2000	
	A16	WO	00/71549	A1	Knoll Aktiengesellschaft	11/30/2000	
→	A17	WO	00/78312	A1	Merck & Co., Inc.	12/28/2000	
	A18	WO	01/09111	A1	Eli Lilly & Co.	2/8/2001	
	A19	WO	01/83451	A1		11/8/2001	
↓	A20	WO	01/85695	A1	Bristol-Myers Squibb	11/15/2001	
↓	A21	WO	01/91752	A1	Merck & Co., Inc.	12/6/2001	
And	A22	DE	10142734	A1	Aventis Pharma Deutschland GmbH	3/27/2003	

**Examiner
Signature**

Ernest W Davis

Date Considered

11/12/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC.



plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. GMD 9051003.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	Unassigned
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSS et al.
Group Art Unit	Unassigned 1625 ECHO
Examiner Name	Unassigned ZNDAVSEN
Attorney Docket Number	38005-0178

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

~~F. W. Davis~~

Date Considered

112 2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC.



please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/616,959
(use as many sheets as necessary)				Filing Date	July 11, 2003
Sheet	4	of	4	First Named Inventor	Elisabeth DEFOSSA et al.
				Group Art Unit	Unassigned 1625
				Examiner Name	Unassigned 2NDAVIS
				Attorney Docket Number	38005-0178

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
<i>mpn</i>	A24	A. ASAKAWA et al., "Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice", Horm. Metab. Res., 2001, pp. 554-558, Vol. 33		
<i>mpn</i>	A25	P. DRUECKES et al., "Photometric Microtiter Assay of Inorganic Phosphate in the Presence of Acid-Labile Organic Phosphates", Analytical Biochemistry, 1995, p. 173-177, Vol. 230		
	A26	H.D. ENGERS et al., "Kinetic mechanism of phosphorylase a. I. Initial velocity studies", Department of Biochemistry, University of Alberta, Edmonston 7, Alberta, January 12, 1970, pp. 746-754		
	A27	DANIEL W. LEE et al., "Leptin agonists as a potential approach to the treatment of obesity", Drugs of the Future, 2001, pp. 873-881, Vol. 26, No. 9		
	A28	HIROSHI OKADA et al., "Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas", Chem. Pharm. Bull., 1994, pp. 57-61, Vol. 42, No. 1		
	A29	JAVIER SALVADOR et al., "Perspectives in the therapeutic use of leptin", Expert Opin. Pharmacother, 2001, 2001, pp. 1615-1622, Vol. 2, No. 10		
<i>mpn</i>	A30	PRAVENN TYLE, "Iontophoretic Devices for Drug Delivery", Pharmaceutical Research, 1986, pp. 318-326, Vol. 3, No. 6		
<i>mpn</i>	A31	H.J.F. ZUNFT et al., "Carob Pulp Preparation for Treatment of Hypercholesterolemia", Advances In Natural Therapy, September/October 2001, pp. 231-236, Vol. 18, No. 5		

Examiner Signature		Date Considered	1/12/2005
--------------------	--	-----------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

Approved for use through 10/31/2002. GPO 0031-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE

1963.3.2

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sh

of 1

Complete if Known	
Application Number	10/616,959
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSA et al.
Group Art Unit	Unassigned 1625
Examiner Name	4614 2ND AAVIS
Attorney Docket Number	38005-0178

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

June A Davis

Date Considered

1/12/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C.